LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

30.91 -0.48

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

30.39

Max

30.92

Galvenie mērījumi
By Trading Economics
Ienākumi	-30M -30M
Pārdošana	-26M 77M
Peļņas marža	-38.823
Darbinieki	524
EBITDA	-12M -8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+113.06% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	30M 1.7B
Iepriekšējā atvēršanas cena	31.39
Iepriekšējā slēgšanas cena	30.91

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 13. marts 19:08 UTC

Galvenie ziņu notikumi

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026. g. 15. marts 23:45 UTC

Tirgus saruna

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026. g. 15. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026. g. 15. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026. g. 15. marts 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026. g. 15. marts 22:37 UTC

Tirgus saruna

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026. g. 15. marts 22:18 UTC

Tirgus saruna

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 03:00 UTC

Galvenie ziņu notikumi

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026. g. 14. marts 15:00 UTC

Galvenie ziņu notikumi

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026. g. 14. marts 02:03 UTC

Peļņas

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026. g. 14. marts 01:32 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026. g. 14. marts 00:29 UTC

Iegādes, apvienošanās, pārņemšana

13D Filings -- Barrons.com

2026. g. 13. marts 22:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026. g. 13. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026. g. 13. marts 22:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026. g. 13. marts 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 20:02 UTC

Tirgus saruna

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026. g. 13. marts 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026. g. 13. marts 19:35 UTC

Galvenie ziņu notikumi

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

113.06% augšup

Prognoze 12 mēnešiem

Vidējais 65.75 USD 113.06%

Augstākais 100 USD

Zemākais 38 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.